Moderna, Inc. (NASDAQ:MRNA) | Finanzwire

Basculer en Français

10238	Companies
211356	Keywords
141292	Articles
111971	Press releases

Home
Companies
Moderna, Inc.

PRESS RELEASE

published on 09/17/2024 at 17:00, 1 year 7 months ago

Moderna Receives Health Canada Approval For Updated COVID-19 Vaccine Targeting KP.2 Variant Of SARS-COV-2 For Ages Six Months And Older
Moderna's SPIKEVAX® KP.2 variant COVID-19 vaccine authorized in Canada for 2024-2025 season to protect against COVID-19 strains. Delivery to begin promptly for vaccination campaigns

COVID-19 Vaccine Health Canada Moderna Spikevax Vaccination Campaigns
BRIEF

published on 09/12/2024 at 12:05, 1 year 7 months ago

Moderna R&D Day Highlights Progress and Strategic Priorities

COVID-19 Vaccine Financial Outlook Vaccine Approvals Moderna Updates R&D Strategy
PRESS RELEASE

published on 09/12/2024 at 12:00, 1 year 7 months ago

Moderna R&D Day Highlights Progress and Strategic Priorities
Moderna, Inc. announces program updates focusing on ten product approvals through 2027, submission of next-gen COVID vaccine and flu/COVID combo vaccine in 2024, positive Phase 3 results for RSV vaccine, and cost efficiency improvements

Moderna Vaccine Phase 3 Results Product Approvals R&D Expense Reduction
BRIEF

published on 09/09/2024 at 13:05, 1 year 7 months ago

Moderna’s Canadian Manufacturing Facility Receives Drug Establishment License From Health Canada

Health Canada Moderna MRNA Vaccines Laval Facility Drug Establishment License
PRESS RELEASE

published on 09/09/2024 at 13:00, 1 year 7 months ago

Moderna’s Canadian Manufacturing Facility Receives Drug Establishment License From Health Canada
Moderna's Laval facility in Canada attains Drug Establishment License, a key step towards onshore mRNA vaccine production by 2025. This milestone boosts national vaccine supply

Canada Manufacturing Facility Moderna MRNA Vaccines Drug Establishment License
BRIEF

published on 09/05/2024 at 14:05, 1 year 7 months ago

EMA Recommends Authorization of Moderna's Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant JN.1

Authorization COVID-19 Vaccine Moderna EMA SARS-CoV-2 Variant
PRESS RELEASE

published on 09/05/2024 at 14:00, 1 year 7 months ago

EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1
Moderna's updated COVID-19 mRNA vaccine targeting SARS-CoV-2 variant JN.1 receives positive opinion from CHMP for European Commission authorization decision for 2024-2025 vaccination season

COVID-19 Vaccine European Commission Moderna MRNA Spikevax
BRIEF

published on 09/03/2024 at 14:35, 1 year 7 months ago

Moderna Receives MHRA Authorization for Updated COVID-19 Vaccine Targeting JN.1 Variant

COVID-19 Moderna Vaccine JN.1 Variant MHRA
PRESS RELEASE

published on 09/03/2024 at 14:30, 1 year 7 months ago

Moderna Receives Medicines And Healthcare Products Regulatory Agency (MHRA) Authorization For Updated COVID-19 Vaccine Targeting SARS-COV-2 Variant JN.1
MHRA authorizes Moderna's updated COVID-19 vaccine targeting JN.1 variant. Available for NHS and private purchase in the UK. Follows WHO recommendation for JN.1 subvariants

COVID-19 Vaccine Moderna JN.1 Variant MHRA Authorization Private Purchase
BRIEF

published on 09/02/2024 at 13:05, 1 year 7 months ago

Taiwan FDA Approves Moderna’s COVID-19 Vaccine Targeting SARS-CoV-2 Variant JN.1

COVID-19 Vaccine Moderna Spikevax Taiwan FDA SARS-CoV-2 JN.1

Accesswire

Published on 04/18/2026 at 04:00, 8 hours 59 minutes ago

Formation Metals Responds to OTC Markets Request on Recent Promotional Activity
Published on 04/18/2026 at 02:00, 10 hours 59 minutes ago

AI/ML Innovations Announces Completion of Share Issuance
Published on 04/18/2026 at 01:35, 11 hours 24 minutes ago

Medicure Announces Resignation of President and Chief Operating Officer
Published on 04/18/2026 at 01:00, 11 hours 59 minutes ago

Onco-Innovations Strengthens Executive Leadership with Appointment of Dr. Islam Mohamed as Chief Medical Officer and Stephen M. Novak as Chief of Research and Development
Published on 04/18/2026 at 00:00, 12 hours 59 minutes ago

Redwood AI Announces Collaboration with Aidos Innovations, Aimed at Enhancing Public Safety Collaboration with B.C. Government, Canadian Federal and Local Law Enforcement Agencies to Tackle the Fentanyl Crisis in British Columbia

View all ACCESSWIRE

EQS Group

Published on 04/18/2026 at 00:05, 12 hours 54 minutes ago

ESCMID Global: Maternal RSV vaccination cuts infant hospitalisation risk by over 80%, major UKHSA study finds
Published on 04/17/2026 at 20:33, 16 hours 25 minutes ago

LLB General Meeting 2026 – Shareholders approve all proposals of the Board of Directors
Published on 04/17/2026 at 19:35, 17 hours 24 minutes ago

Stabilisation Notice
Published on 04/17/2026 at 19:30, 17 hours 29 minutes ago

KAP AG: REFINANCING CONCEPT AGREED; NEW SYNDICATED LOAN SECURES FLEXIBILITY FOR THE ONGOING TRANSFORMATION PROCESS
Published on 04/17/2026 at 19:29, 17 hours 30 minutes ago

EQS-Adhoc: KAP AG: KAP AG: REFINANCING CONCEPT AGREED; TERM OF EXISTING SYNDICATED LOAN EXTENDED BY THREE YEARS

Les Echos

Published on 04/17/2026 at 19:00, 17 hours 59 minutes ago

Cegedim: Release of its 2025 Universal Registration Document
Published on 04/17/2026 at 17:45, 19 hours 14 minutes ago

Carrefour announces the sale of its minority stake in CarrefourSA in Turkey to Aydın
Published on 04/17/2026 at 15:26, 21 hours 33 minutes ago

Statement about the number of shares composing the share capital and the number of voting rights as of March 31, 2026
Published on 04/17/2026 at 09:10, 1 day 3 hours ago

Number of shares and voting rights - March 2026 (In French only)
Published on 04/16/2026 at 18:02, 1 day 18 hours ago

Covivio - Description of the share buy-back program authorized by the Combined Ordinary and Extraordinary Shareholders’ Meeting held on 16 April 2026

View all LES ECHOS COMFI WIRE